Dr. Hemrock studies various rare types of cancer that are often overlooked or misdiagnosed. She focuses on conditions like pulmonary pleomorphic carcinoma, primary mucinous adenocarcinoma of the eyelid, squamous cell carcinoma of the thyroid, and uterine carcinosarcoma. Her research highlights the importance of early detection in unusual cancers and the unique challenges these conditions present, both in diagnosis and treatment options. She also investigates the side effects of cancer therapies, particularly immune checkpoint inhibitors, raising awareness of how such treatments can affect patients beyond just cancer.
Key findings
Asbestos exposure can lead to the development of pulmonary pleomorphic carcinoma in non-smokers, as seen in a case study of an 88-year-old patient.
Primary mucinous adenocarcinoma of the eyelid occurs in only 0.07 people per million and can grow aggressively, necessitating prompt surgical and therapeutic interventions.
Primary squamous cell carcinoma of the thyroid is extremely rare, making up less than 1% of thyroid cancers, and often requires immediate attention due to its aggressive nature.
In patients with recurrent small cell lung cancer treated with immune checkpoint inhibitors, serious neurological side effects such as brain stem encephalitis can occur, impacting treatment plans.
Uterine carcinosarcoma accounts for less than 5% of all uterine cancers and can present in young women with severe symptoms, indicating the need for greater awareness and appropriate treatment strategies.
Frequently asked questions
Does Dr. Hemrock study lung cancer?
Yes, she studies various types of lung cancers, including rare forms like pulmonary pleomorphic carcinoma.
What types of cancer has Dr. Hemrock researched?
She has researched several rare cancers including eyelid cancer, thyroid cancer, and uterine carcinosarcoma.
Are Dr. Hemrock's findings relevant for patients experiencing unusual cancer symptoms?
Yes, her research is crucial for patients with rare cancers as it highlights symptoms and treatment options that may be overlooked.
What treatments has Dr. Hemrock researched?
She has looked into various treatments including surgery, chemotherapy, and immune therapies like nivolumab, focusing on their effectiveness and side effects.
Is Dr. Hemrock's work important for understanding cancer risks?
Absolutely, her work underscores the significance of environmental factors like asbestos exposure in developing cancers, even in non-smokers.
Publications in plain English
Asbestos Exposure and Development of Pulmonary Pleomorphic Carcinoma in a Non-smoker: A Rare Non-small Cell Lung Cancer.
2023
Cureus
Alejo AL, Patel RA, Pandya KK, Bodrya K, Goldstein L +1 more
Plain English This study examined a rare type of lung cancer called pulmonary pleomorphic carcinoma (PPC) in an 88-year-old man who had never smoked but had been exposed to asbestos. Despite his age and the rarity of PPC, doctors were able to make a diagnosis after he experienced unusual fluid buildup in his lungs. The findings emphasize that even non-smokers can develop serious lung cancer due to environmental factors like asbestos exposure, which points to the importance of thorough screening for such risk factors when diagnosing lung diseases.
Who this helps: This helps patients who have had asbestos exposure and healthcare providers managing lung cancer diagnoses.
Uterine Carcinosarcoma in a Young Female: Case Report and Literature Review.
2021
Cureus
Soror NN, Woredekal D, Hemrock L, Gibson G, Bennett R
Plain English The research looked at a rare and aggressive type of uterine cancer called uterine carcinosarcoma (USC), which typically affects older women but was found in a young Caucasian woman. This patient experienced symptoms like nausea and severe anemia and highlighted that USC makes up less than 5% of all uterine cancers, is more common in black women, and has a worse prognosis than other types of uterine cancer. Understanding more about this rare cancer is important for improving diagnosis and treatment options.
Who this helps: This helps patients and doctors by increasing awareness of USC in younger women and its symptoms.
Brain Stem Encephalitis in a Patient With Recurrent Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor: Case Presentation and Review of the Literature.
2021
Cureus
Soror NN, Hemrock L, Shah P, Loges RJ, Tharu B
Plain English This study focuses on a patient with recurrent small cell lung cancer who developed a rare brain condition called brain stem encephalitis after receiving an immune therapy drug called nivolumab. After 10 months of treatment, the patient experienced symptoms like blurry vision and trouble walking. After stopping the drug and starting steroids, her condition gradually improved, but symptoms returned when she tried the drug again; however, she managed to stay stable without treatment for six months after that.
Who this helps: This information benefits doctors treating cancer patients with immune therapies by raising awareness about potential neurological side effects.
Primary Squamous Cell Carcinoma of the Thyroid: A Case Report and Literature Review About a Rare Entity.
2021
Cureus
Soror NN, Shah P, Hemrock L, Bennett R
Plain English This study looked at primary squamous cell carcinoma of the thyroid, a rare and aggressive type of cancer that makes up less than 1% of all thyroid cancers. The researchers described a case of a man with a quickly growing neck mass, highlighting the challenges in diagnosing and treating this condition, as it often lacks established treatment guidelines. Understanding this cancer is important because it affects a small number of people, but when it does occur, it tends to be more common in middle-aged women and requires immediate attention.
Who this helps: Patients diagnosed with this rare form of thyroid cancer and their healthcare providers.
A Rare Case of Primary Adenocarcinoma of the Eyelid: Case Presentation and Review of Literature.
2021
Cureus
Soror NN, Lutaya I, Shah P, Hemrock L, Bennett R +1 more
Plain English This paper discusses a rare type of eyelid cancer called primary mucinous adenocarcinoma (PMA), which affects only 0.07 people per million. The case highlighted is about a 61-year-old man whose PMA was aggressive, leading to significant tumor growth in the eyelid and surrounding areas. After confirming the diagnosis through a biopsy and imaging, he underwent major surgery and additional treatments including radiation and chemotherapy, highlighting the difficulty in diagnosing and managing this cancer.
Who this helps: This helps patients with eyelid tumors and doctors managing rare cancers.